| Autor: |
Sturm N; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Schuhbaur JS; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Hüttner F; Department of General and Visceral Surgery, Ulm University Hospital, 89081 Ulm, Germany., Perkhofer L; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Ettrich TJ; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2022 Nov 14; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 14. |
| DOI: |
10.3390/cancers14225580 |
| Abstrakt: |
Gallbladder cancer (GBC) is the most common primary tumor site of biliary tract cancer (BTC), accounting for 0.6% of newly diagnosed cancers and 0.9% of cancer-related deaths. Risk factors, including female sex, age, ethnic background, and chronic inflammation of the gallbladder, have been identified. Surgery is the only curative option for early-stage GBC, but only 10% of patients are primary eligible for curative treatment. After neoadjuvant treatment, up to one-third of locally advanced GBC patients could benefit from secondary surgical treatment. After surgery, only a high-risk subset of patients benefits from adjuvant treatment. For advanced-stage GBC, palliative chemotherapy with gemcitabine and cisplatin is the current standard of care in line with other BTCs. After the failure of gemcitabine and cisplatin, data for second-line treatment in non-resectable GBC is poor, and the only recommended chemotherapy regimen is FOLFOX (5-FU/folinic acid and oxaliplatin). Recent advances with the PD-L1 inhibitor durvalumab open the therapy landscape for immune checkpoint inhibition in GBC. Meanwhile, targeted therapy approaches are a cornerstone of GBC therapy based on molecular profiling and new evidence of molecular differences between different BTC forms and might further improve the prognosis of GBC patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
